U.S. Markets open in 1 hr 53 mins

Alzamend Neuro, Inc. (ALZN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.2700+0.0100 (+0.44%)
At close: 4:00PM EDT
2.2800 +0.01 (+0.44%)
Pre-Market: 07:19AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.2600
Bid2.2700 x 2900
Ask2.3200 x 3200
Day's Range2.2200 - 2.3650
52 Week Range2.2200 - 33.5500
Avg. Volume2,760,446
Market Cap192.79M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks

    Company News for Oct 1, 2021

    Companies in the news are: PAYX, SPCE, ALZN, OG

  • Benzinga

    51 Biggest Movers From Yesterday

    Gainers Superior Drilling Products, Inc. (NYSE: SDPI) shares rose 60.6% to close at $1.75 on Thursday after jumping over 23% on Wednesday. The company, last month, reported Q2 earnings of $0.00 per share on sales of $3.40 million. Progenity, Inc. (NASDAQ: PROG) jumped 40.7% to close at $1.52 after jumping around 22% on Wednesday. Progenity recently announced the USPTO has issued U.S. Patent No. 11,112,403 for assessment of preeclampsia using assays for free and dissociated placental growth facto

  • Benzinga

    See Why Alzamend Neuro Stock Is Rallying On Thursday

    Alzamend Neuro Inc (NASDAQ: ALZN) has received a written response to its meeting request regarding the FDA's Type B Pre‑Investigational New Drug (Pre-IND) application. Today's response provides a path for its planned clinical development of AL002, the Company says. AL002 uses a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's. The FDA agreed to Alzamend's proposed combined Phase 1/2 stud